Dakota L. Jones
Mayo Clinic
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Dakota L. Jones.
Journal of Orthopaedic Research | 2016
Matthew A. Getzlaf; Eric A. Lewallen; Hilal Maradit Kremers; Dakota L. Jones; Carolina A. Bonin; Amel Dudakovic; Roman Thaler; Robert C. Cohen; David G. Lewallen; Andre J. van Wijnen
Like any foreign object, orthopaedic implants are susceptible to infection when introduced into the human body. Without additional preventative measures, the absolute number of annual prosthetic joint infections will continue to rise, and may exceed the capacity of health care systems in the near future. Bacteria are difficult to eradicate from synovial joints due to their exceptionally diverse taxonomy, complex mechanistic attachment capabilities, and tendency to evolve antibiotic resistance. When a primary orthopaedic implant fails from prosthetic joint infection, surgeons are generally challenged by limited options for intervention. In this review, we highlight the etiology and taxonomic groupings of bacteria known to cause prosthetic joint infections, and examine their key mechanisms of attachment. We propose that antimicrobial strategies should focus on the most harmful bacteria taxa within the context of occurrence, taxonomic diversity, adhesion mechanisms, and implant design. Patient‐specific identification of organisms that cause prosthetic joint infections will permit assessment of their biological vulnerabilities. The latter can be targeted using a range of antimicrobial techniques that exploit different colonization mechanisms including implant surface attachment, biofilm formation, and/or hematogenous recruitment. We anticipate that customized strategies for each patient, joint, and prosthetic component will be most effective at reducing prosthetic joint infections, including those caused by antibiotic‐resistant and polymicrobial bacteria.
Journal of Orthopaedic Research | 2016
Yang Lin; Eric A. Lewallen; Emily T. Camilleri; Carolina A. Bonin; Dakota L. Jones; Amel Dudakovic; Catalina Galeano-Garces; Wei Wang; Marcel Karperien; Annalise N. Larson; Diane L. Dahm; Michael J. Stuart; Bruce A. Levy; Jay Smith; Daniel B. Ryssman; Jennifer J. Westendorf; Hee-Jeong Im; Andre J. van Wijnen; Scott M. Riester; Aaron J. Krych
Preservation of osteochondral allografts used for transplantation is critical to ensure favorable outcomes for patients after surgical treatment of cartilage defects. To study the biological effects of protocols currently used for cartilage storage, we investigated differences in gene expression between stored allograft cartilage and fresh cartilage from living donors using high throughput molecular screening strategies. We applied next generation RNA sequencing (RNA‐seq) and real‐time reverse transcription quantitative polymerase chain reaction (RT‐qPCR) to assess genome‐wide differences in mRNA expression between stored allograft cartilage and fresh cartilage tissue from living donors. Gene ontology analysis was used to characterize biological pathways associated with differentially expressed genes. Our studies establish reduced levels of mRNAs encoding cartilage related extracellular matrix (ECM) proteins (i.e., COL1A1, COL2A1, COL10A1, ACAN, DCN, HAPLN1, TNC, and COMP) in stored cartilage. These changes occur concomitantly with increased expression of “early response genes” that encode transcription factors mediating stress/cytoprotective responses (i.e., EGR1, EGR2, EGR3, MYC, FOS, FOSB, FOSL1, FOSL2, JUN, JUNB, and JUND). The elevated expression of “early response genes” and reduced levels of ECM‐related mRNAs in stored cartilage allografts suggests that tissue viability may be maintained by a cytoprotective program that reduces cell metabolic activity. These findings have potential implications for future studies focused on quality assessment and clinical optimization of osteochondral allografts used for cartilage transplantation.
Gene | 2016
Eric A. Lewallen; Dakota L. Jones; Amel Dudakovic; Roman Thaler; Christopher R. Paradise; Hilal Maradit Kremers; Matthew P. Abdel; Sanjeev Kakar; Allan B. Dietz; Robert C. Cohen; David G. Lewallen; Andre J. van Wijnen
Integration of porous metal prosthetics, which restore form and function of irreversibly damaged joints, into remaining healthy bone is critical for implant success. We investigated the biological properties of adipose-tissue-derived mesenchymal stromal/stem cells (AMSCs) and addressed their potential to alter the in vitro microenvironment of implants. We employed human AMSCs as a practical source for musculoskeletal applications because these cells can be obtained in large quantities, are multipotent, and have trophic paracrine functions. AMSCs were cultured on surgical-grade porous titanium disks as a model for orthopedic implants. We monitored cell/substrate attachment, cell proliferation, multipotency, and differentiation phenotypes of AMSCs upon osteogenic induction. High-resolution scanning electron microscopy and histology revealed that AMSCs adhere to the porous metallic surface. Compared to standard tissue culture plastic, AMSCs grown in the porous titanium microenvironment showed differences in temporal expression for genes involved in cell cycle progression (CCNB2, HIST2H4), extracellular matrix production (COL1A1, COL3A1), mesenchymal lineage identity (ACTA2, CD248, CD44), osteoblastic transcription factors (DLX3, DLX5, ID3), and epigenetic regulators (EZH1, EZH2). We conclude that metal orthopedic implants can be effectively seeded with clinical-grade stem/stromal cells to create a pre-conditioned implant.
Stem Cells Translational Medicine | 2017
Scott M. Riester; Janet M. Denbeigh; Yang Lin; Dakota L. Jones; Tristan de Mooij; Eric A. Lewallen; Hai Nie; Christopher R. Paradise; Darcie J. Radel; Amel Dudakovic; Emily T. Camilleri; Dirk R. Larson; Wenchun Qu; Aaron J. Krych; Matthew A. Frick; Hee Jeongim Im; Allan B. Dietz; Jay Smith; Andre J. van Wijnen
Adipose‐derived mesenchymal stem cells (AMSCs) offer potential as a therapeutic option for clinical applications in musculoskeletal regenerative medicine because of their immunomodulatory functions and capacity for trilineage differentiation. In preparation for a phase I clinical trial using AMSCs to treat patients with osteoarthritis, we carried out preclinical studies to assess the safety of human AMSCs within the intra‐articular joint space. Culture‐expanded human AMSCs grown in human platelet‐lysate were delivered via intra‐articular injections into normal healthy rabbit knees and knees at risk for the development of osteoarthritis after bilateral medial anterior hemimeniscectomy. Treatment outcomes and safety were evaluated by assessing the general health, function, and behavior of the animals. Joint tissues were analyzed by x‐ray, magnetic resonance imaging, and histopathology. Intra‐articular AMSC therapy was well tolerated in this study. We did not observe adverse systemic reactions, nor did we find evidence of damage to intra‐articular joint tissues. Thus, the data generated in this study show a favorable safety profile for AMSCs within the joint space in support of a phase I clinical trial evaluating the clinical utility of AMSCs to treat osteoarthritis. Stem Cells Translational Medicine 2017;6:910–922
Pm&r | 2016
Kentaro Onishi; Dakota L. Jones; Scott M. Riester; Eric A. Lewallen; David G. Lewallen; Jacob L. Sellon; Allan B. Dietz; Wenchun Qu; Andre J. van Wijnen; Jay Smith
To assess the biological effects of passage through clinically relevant needles on the viability and metabolic activity of culture‐expanded, human adipose tissue–derived mesenchymal stromal/stem cells (AMSCs).
Journal of Orthopaedic Research | 2016
Matthew A. Getzlaf; Eric A. Lewallen; Hilal Maradit Kremers; Dakota L. Jones; Carolina A. Bonin; Amel Dudakovic; Roman Thaler; Robert C. Cohen; David G. Lewallen; Andre J. van Wijnen
Like any foreign object, orthopaedic implants are susceptible to infection when introduced into the human body. Without additional preventative measures, the absolute number of annual prosthetic joint infections will continue to rise, and may exceed the capacity of health care systems in the near future. Bacteria are difficult to eradicate from synovial joints due to their exceptionally diverse taxonomy, complex mechanistic attachment capabilities, and tendency to evolve antibiotic resistance. When a primary orthopaedic implant fails from prosthetic joint infection, surgeons are generally challenged by limited options for intervention. In this review, we highlight the etiology and taxonomic groupings of bacteria known to cause prosthetic joint infections, and examine their key mechanisms of attachment. We propose that antimicrobial strategies should focus on the most harmful bacteria taxa within the context of occurrence, taxonomic diversity, adhesion mechanisms, and implant design. Patient‐specific identification of organisms that cause prosthetic joint infections will permit assessment of their biological vulnerabilities. The latter can be targeted using a range of antimicrobial techniques that exploit different colonization mechanisms including implant surface attachment, biofilm formation, and/or hematogenous recruitment. We anticipate that customized strategies for each patient, joint, and prosthetic component will be most effective at reducing prosthetic joint infections, including those caused by antibiotic‐resistant and polymicrobial bacteria.
Journal of Orthopaedic Research | 2016
Matthew A. Getzlaf; Eric A. Lewallen; Hilal Maradit Kremers; Dakota L. Jones; Carolina A. Bonin; Amel Dudakovic; Roman Thaler; Robert C. Cohen; David G. Lewallen; Andre J. Van Wijnen
Like any foreign object, orthopaedic implants are susceptible to infection when introduced into the human body. Without additional preventative measures, the absolute number of annual prosthetic joint infections will continue to rise, and may exceed the capacity of health care systems in the near future. Bacteria are difficult to eradicate from synovial joints due to their exceptionally diverse taxonomy, complex mechanistic attachment capabilities, and tendency to evolve antibiotic resistance. When a primary orthopaedic implant fails from prosthetic joint infection, surgeons are generally challenged by limited options for intervention. In this review, we highlight the etiology and taxonomic groupings of bacteria known to cause prosthetic joint infections, and examine their key mechanisms of attachment. We propose that antimicrobial strategies should focus on the most harmful bacteria taxa within the context of occurrence, taxonomic diversity, adhesion mechanisms, and implant design. Patient‐specific identification of organisms that cause prosthetic joint infections will permit assessment of their biological vulnerabilities. The latter can be targeted using a range of antimicrobial techniques that exploit different colonization mechanisms including implant surface attachment, biofilm formation, and/or hematogenous recruitment. We anticipate that customized strategies for each patient, joint, and prosthetic component will be most effective at reducing prosthetic joint infections, including those caused by antibiotic‐resistant and polymicrobial bacteria.
American Journal of Respiratory Cell and Molecular Biology | 2018
Dakota L. Jones; Giovanni Ligresti
Archive | 2016
Kentaro Onishi; Dakota L. Jones; Scott M. Riester; Eric A. Lewallen; David G. Lewallen; Jacob L. Sellon; Allan B. Dietz; Wenchun Qu; Andre J. van Wijnen; Jay Smith
Archive | 2015
Roman Thaler; Markus Schreiner; Chris Paradise; Dakota L. Jones; Dudakovic Amel; Allan B. Dietz; Wijnen Andre van